AlenCiken 의 NASDAQ:EKSO 용 Receives FDA Clearance to Market its EksoNR™

Ekso Bionics® Receives FDA Clearance to Market its EksoNR™ Robotic Exoskeleton for Use with Acquired Brain Injury Patients
-------------------------------------------------------------
announced it has received 501(k) clearance from the U.S. FDA to market its EksoNRTM robotic exoskeleton for use with patients with acquired brain injury (ABI).
------------------------------------------------------
EksoNR is the first exoskeleton device to receive FDA clearance for rehabilitation use with ABI, significantly expanding the device’s indication to a broader group of patients.

Ekso, based in Richmond, California, had a net loss of $2.5 million in its latest quarter, narrower than the loss of $6.6 million posted in the year-earlier period. Revenue came to $1.5 million, down from $3.6 million, as the pandemic led some customers to delay orders.